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Purpose: The cognitive side effects of whole brain radiotherapy 
(WBRT) are well recognized, as is the importance of local disease 
control on neurocognitive function. We therefore set out to 
assess the neurocognitive impact of a central nervous system 
(CNS) event in patients that received volumetric radiosurgery 
(VRS) and WBRT to aid in defining a subgroup of patients 
receiving radiosurgery that may preserve cognition with WBRT. 
Methods and Materials: This multicentre Phase 2, single-arm 
study accrued 60 patients with one to ten brain metastases. 
Eligible patients received 47.5 Gy in 5 fractions VRS to their 
metastases concurrent with 20 Gy in 5 fractions to the whole 
brain. Cognitive assessment was a secondary endpoint in the 
trial. Neurocognitive function was assessed using the Mini-Mental 
State Examination (MMSE). It was analyzed at baseline and at 
three-month intervals, until the 12-month follow up point. An 
MMSE drop of 3 points, which is the minimal clinically significant 
difference, was defined as a cognitive event. A CNS event was 
defined as local recurrence, distant brain relapse or 
radionecrosis. 
Results: From July 2010 to May 2013, 60 patients, with a median 
age of 62 years, underwent treatment. Median survival was 10.1 
months. Twenty-seven patients (45%) had a CNS event in the first 
12 months after treatment. Sixteen patients (59%) developed 
distant brain relapse, five (19%) local relapse, and six (22%) 
radionecrosis. On univariate analysis, the risk of a CNS event 
(hazard ratio (HR = 5.4, p = 0.03). was significantly associated 
with the risk of first 3 point drop in MMSE. On multivariate 
analysis, both age (HR = 4.5, p = 0.03) and CNS event (HR =11.6, 
p = 0.03) were significantly associated with a cognitive event. 
The risk of a first 3-point drop in MMSE was found to be highest 
in patients above median age that experienced a CNS event. 
Conclusions: The results of this study showed that control of CNS 
events is the most import factor in maintaining neurocognitive 
function in patients with one to ten brain metastases. It 
determined that a clinically significant drop in MMSE was 
associated with local recurrence, distant brain relapse or 
radionecrosis, as well as older age. In patients treated with 
WBRT, it highlights the importance of age on neurocognitive 
function, as older patients with a CNS event were more at risk of 
a cognitive event. Using WBRT adjuvantly to preserve cognitive 
function, should be considered in younger patients with a high-
risk of distant brain relapse. 
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Introduction:  Randomized Controlled Trials (RCT), particularly 
of rare tumour groups, often have issues with patient accrual, 
which necessitates a multicentre approach to achieve accrual 
targets. Logistically, investigators of multicentre trials face 
issues in efficient data management in terms of accuracy, 
transfer, security, and quality assurance. Historically, paper-
based report forms to collect patient baseline and regular follow 
up data have made these issues challenging. 
Purpose: To discuss the use of electronic forms (eForms) used 
for our glioblastoma multiforme (GBM) trial study. Various 
limitations and advantages of the use of eForms are discussed 
and compared to paper based and other internet based data 
collection methods 
Methods and Materials: Specially formatted computer based PDF 
forms were completed to gather patient by the investigators for 
screening and eligibility data (eForm A and B), as well as baseline 
QOL eForms (quality of life data according to EORTC QLQ-C30 
and QLQ-BN20 questionnaires). After randomization, radiation 
treatment details (eForm C) and QOL data were collected. eForm 
D was used to collect follow up data. All of these forms were 
completed by the participating centre and then emailed as an 
attachment to the Data Management Centre (DMC). A short 
satisfaction survey was sent to the physicians of the participating 
centres after the completion of the study. 
Results: For this study, there were 12 participating centres from 
around the world. There were no issues overall with data 
collection using the eForms. The costs associated with the 
development of the eForms were minimal as well. The forms 
were a convenient way of sending patient trial data via email to 
the DMC. The results of the short survey agree with our 
experience. About 90% of the participating sites found the design 
of the forms to be user-friendly, and did not have any problems 
accessing, completing, and submitting the files from their 
computer. Most of the participants found the eForms to be very 
practical, efficient, and standardized. About 20% of the 
participants found the need for a guide to be associated with the 
eForms for better standardization and minimizing bias. We did 
not find any problems with the security of using eForms as well.  
Conclusions:  In the setting of multicentre trials, using eForms 
for data management proved to be efficient, convenient, and 
reliable. Future multicentre trials may benefit from similar data 
management systems to improve data collection and analysis. 
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Purpose: Stereotactic ablative radiotherapy (SABR) is a 
guideline-specified treatment option for early-stage lung cancer. 
However, significant post-treatment fibrosis can occur and 
confound the detection of local recurrence. The goal of this 
study was to assess physician ability to detect timely local 
recurrence on computed tomography (CT) imaging, and compare 
physician performance with that of a radiomics tool. Radiomics 
aims to extract more complex information from medical images, 
including features not easily visible with the naked eye. 
Methods and Materials: CT scans of 45 patients (15 with proven 
local recurrence matched to 30 with no local recurrence) were 
used to measure physician and radiomic performance in assessing 
response. Scans were individually scored by three thoracic 
radiation oncologists and three thoracic radiologists, all of whom 
